High ST6GAL1 expression promotes an immune‐activated tumor microenvironment (TME), characterized by increased infiltration of CD8+ T cells and M1 macrophages, thereby improving sensitivity to immunotherapy. This evidence concerns the gene CD8A and neoplasm.